Neurofibromin Deficiency and Extracellular Matrix Cooperate to Increase Transforming Potential through FAK-Dependent...

Area of Science:

• Oncology
• Cell Biology
• Genetics

Background:

• Plexiform neurofibromas (PNFs) are hallmark tumors of neurofibromatosis type 1 (NF1).
• PNFs arise from Schwann cells lacking neurofibromin (Nfn), a key Ras regulator, due to NF1 gene loss.
• The tumor microenvironment, including extracellular matrix (ECM) and stromal cells, significantly influences PNFs and their progression to malignant peripheral nerve sheath tumors (MPNSTs).

Purpose of the Study:

• To investigate the role of the ECM in the growth of Nfn-deficient cells relevant to PNFs.
• To identify potential therapeutic targets and strategies for treating PNFs.

Main Methods:

• Utilized a 3D in vitro culture system mimicking the PNF microenvironment.
• Assessed the effects of Nfn deficiency on cell signaling pathways, including focal adhesion kinase (FAK), Src, ERK, and AKT.
• Evaluated the efficacy of single-agent treatments (Nfn expression, FAK inhibitor Defactinib, MEK inhibitor Selumetinib) and a combination therapy (Defactinib + Selumetinib).

Main Results:

• NF1 loss sensitized cells to PNF-mimicking ECM signals, leading to FAK hyperactivation, downstream signaling (Src, ERK, AKT), and colony formation.
• Restoring Nfn partially reduced signaling and slowed colony growth.
• Combined treatment with Defactinib and Selumetinib completely inhibited 3D colony growth.

Conclusions:

• The ECM plays a critical role in promoting the growth of Nfn-deficient cells in PNFs via FAK hyperactivation.
• Targeting both FAK and MEK pathways simultaneously offers a promising therapeutic strategy for PNFs by disrupting tumor cell-ECM interactions and intracellular signaling.